Clinical Trials Directory

Trials / Completed

CompletedNCT00713609

Safety and Efficacy Study of Clindamycin/Benzoyl Peroxide/Tazarotene Cream in Subjects With Acne

A Multi-center, Randomized, Double-blind, Vehicle-Controlled, Phase 2 Study of the Safety and Efficacy of Benzoyl Peroxide/Clindamycin Gel and Tazarotene Cream When Used in Combination in the Treatment of Acne Vulgaris

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
591 (actual)
Sponsor
Stiefel, a GSK Company · Industry
Sex
All
Age
12 Years – 45 Years
Healthy volunteers
Not accepted

Summary

Benzoyl peroxide, clindamycin and tazarotene are known to be effective treatment alternative for acne vulgaris. The purpose of this study is to assess the safety and efficacy of a combination product including these actives for the treatment of acne vulgaris. You may be suitable to take part in this study because you have acne vulgaris on your face. Acne vulgaris usually affects the face, but it can also affect the skin on the chest, arms, legs, and back.

Detailed description

The study subjects must have acne vulgaris and will apply study drug to their face for 12 weeks. Study visits will occur at baseline (day 1) and at weeks 2, 4, 8, and 12. Subjects will be assessed at every visit to determine how the study drug is working. Safety will be assessed by evaluation of adverse events (AEs), vital signs, physical examinations, and withdrawals from the study.

Conditions

Interventions

TypeNameDescription
DRUGBenzoyl peroxide gel5% benzoyl peroxide in a gel applied topically once a day
DRUGClindamycin gel1% clindamycin phosphate applied topically once a day
DRUGTazarotene cream0.1 % tazarotene in a cream applied topically once a day
DRUGVehicle gelVehicle gel is an identical gel without the active ingredients
DRUGVehicle creamVehicle cream is an identical cream without the active ingredients

Timeline

Start date
2008-06-01
Primary completion
2009-03-01
Completion
2009-03-01
First posted
2008-07-11
Last updated
2017-03-06
Results posted
2017-03-06

Locations

16 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00713609. Inclusion in this directory is not an endorsement.